Stockscreener 앱 받기
397.55
3.65%
-15.08
시간 외 거래:
397.94
0.39
+0.10%
전일 마감가:
$412.63
열려 있는:
$408.86
하루 거래량:
1.61M
Relative Volume:
1.49
시가총액:
$52.52B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,653.01
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
-13.22%
1개월 성능:
-12.19%
6개월 성능:
+30.49%
1년 성능:
+62.09%
1일 변동 폭
$387.03
$410.04
1주일 범위
$387.03
$449.78
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase - simplywall.st
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern - Seeking Alpha
Seagate, Alnylam among six companies set to join Nasdaq 100 - MSN
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index - GuruFocus
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG - MarketBeat
Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100 - Bloomberg.com
Annual Changes to the Nasdaq-100 Index® - GlobeNewswire Inc.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Nasdaq
How Good Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), When It Comes To ROE? - Yahoo Finance
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge? - simplywall.st
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 - BioSpace
Is Alnylam Pharmaceuticals Stock Built to Withstand More Downside? - Trefis
$73 Billion Non-Opioid Therapeutics Industry Assessment, - GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00 - MarketBeat
WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase - GuruFocus
Alnylam Pharmaceuticals stock price target raised by Stifel to $508 - Investing.com
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News - GuruFocus
Alnylam to repurchase $34.4 million of convertible notes - Investing.com
Alnylam Pharma Announces Convertible Notes Buyback - TipRanks
Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Alnylam Pharmaceuticals, Inc. Announces Partial Repurchase of Convertible Notes - TradingView — Track All Markets
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
authID (NASDAQ: AUID) PrivacyKey named 2025 PayTech Awards Best Digital Trust Solution - Stock Titan
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5%Here's Why - MarketBeat
Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 24%? - Yahoo Finance
How (ALNY) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals a Millionaire Maker? - Finviz
Is Alnylam Pharmaceuticals a millionaire maker? - MSN
Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative - simplywall.st
Can Alnylam Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Marshall Wace LLP Sells 30,359 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Volume & AI Optimized Trade Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesMarket Sentiment Review & Risk Controlled Daily Trade Plans - Newser
Dodge & Cox Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosInsider Buying & Short-Term Trading Alerts - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiples2025 Market Sentiment & Community Driven Trade Alerts - Newser
Do Alnylam Pharmaceuticals’ (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
0.91%
자본화:
|
볼륨(24시간):